Randoll Sze Net Worth

The estimated Net Worth of Randoll Sze is at least $944 mil dollars as of 10 September 2020. Mr. Sze owns over 1,000 units of Athenex Inc stock worth over $1,200 and over the last 6 years he sold ATNX stock worth over $0. In addition, he makes $942,989 as Chief Financial Officer at Athenex Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Sze ATNX stock SEC Form 4 insiders trading

Randoll has made over 6 trades of the Athenex Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of ATNX stock worth $11,400 on 10 September 2020.

The largest trade he's ever made was buying 1,000 units of Athenex Inc stock on 10 September 2020 worth over $11,400. On average, Randoll trades about 667 units every 74 days since 2018. As of 10 September 2020 he still owns at least 6,000 units of Athenex Inc stock.

You can see the complete history of Mr. Sze stock trades at the bottom of the page.

Randoll Sze biography

Randoll Sze is Chief Financial Officer of the company. Prior to his appointment and since October 2017, Mr. Sze served as our Director of Corporate Development and Investor Relations, Asia Pacific. Prior to joining us, Mr. Sze began his career at Credit Suisse (Hong Kong) Limited (“Credit Suisse”) in 2006, and was most recently a Director in its Investment Banking and Capital Markets Division in Hong Kong, a position he held from January 2016 to September 2017. While at Credit Suisse, Mr. Sze worked primarily on financing and strategic advisory transactions for both private and public companies. Mr. Sze obtained a B.S. from University of California, Berkeley, and an M.S. degree from Columbia University.

What is the salary of Randoll Sze?

As the Chief Financial Officer of Athenex Inc, the total compensation of Randoll Sze at Athenex Inc is $942,989. There are 3 executives at Athenex Inc getting paid more, with Johnson Lau having the highest compensation of $4,483,840.

How old is Randoll Sze?

Randoll Sze is 39, he's been the Chief Financial Officer of Athenex Inc since 2018. There are 17 older and no younger executives at Athenex Inc. The oldest executive at Athenex Inc is John Vierling, 74, who is the Independent Director.

What's Randoll Sze's mailing address?

Randoll's mailing address filed with the SEC is C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO, NY, 14203.

Insiders trading at Athenex Inc

Over the last 7 years, insiders at Athenex Inc have traded over $33,215,399 worth of Athenex Inc stock and bought 5,920,005 units worth $73,651,360 . The most active insiders traders include Advisors Llcperceptive Life..., Song Yi Zhang, eSong Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of $10,843. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth $125.

What does Athenex Inc do?

athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.

Complete history of Mr. Sze stock trades at Athenex Inc

Athenex Inc executives and stock owners

Athenex Inc executives and other stock owners filed with the SEC include:

• Johnson Lau,
  Chief Executive Officer and Chairman of the Board
• Rudolf Kwan,
  Chief Medical Officer
• Jeffrey Yordon,
  Chief Operating Officer and President, Athenex Pharmaceutical Division
• Randoll Sze,
  Chief Financial Officer
• Simon Pedder,
  Chief Business and Strategy Officer - Proprietary Products
• Jeffrey M. Yordon,
  COO & Pres of Athenex Pharmaceutical Division
• Dr. Rudolf Kwan M.D., M.B., B.S.,
  Chief Medical Officer
• Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D.,
  Chairman & CEO
• Benson Tsang,
  Independent Director
• Stephanie Davis,
  Independent Director
• Kim Campbell,
  Lead Independent Director
• Jinn Wu,
  Independent Director
• Jordan Kanfer,
  Independent Director
• John Vierling,
  Independent Director
• Manson Fok,
  Director
• Robert Spiegel,
  Director
• Daniel Lang,
  Senior Director - Corporate Development, President - Axis Therapeutics Limited
• Tim McCarthy,
  IR Contact Officer
• William Zuo,
  President, China Division
• Dr. Wing-Kai Chan,
  Deputy Chief Medical Officer of Orascovery & Src Kinase Platforms
• John W. Matthei,
  VP of HR
• Caileigh Dougherty,
  Director of Investor Relations
• Michael Smolinski Ph.D.,
  Chief Scientific Officer
• Steven J. Adams,
  Interim Chief Accounting Officer
• Daniel Lang M.D.,
  Sr. Director of Corp. Devel.
• Jacqueline Li,
  Director of Corp. Devel. & Investor Relations
• Steven Rubis,
  Sr. Director of Investor Relations
• Teresa Brophy Bair,
  Gen. Counsel, Sr. VP of Admin. & Corp. Sec.
• Dr. Allen Barnett,
  Co-Founder & Pres Emeritus
• James Zukin,
  
• Michael D Cannon,
  
• J Nick Riehle,
  Chief Financial Officer
• Antony Leung,
  
• Song Yi Zhang,
  Director
• John Koh,
  Director
• Advisors Llcperceptive Life...,
  
• Sheldon Trainor Degirolamo,
  Director
• Timothy De Vere Cook,
  See Remarks
• Teresa Brophy Bair,
  General Counsel, SVP Admin.
• Joe Annoni,
  Chief Financial Officer
• Steven J. Adams,
  Interim Chief Acct Officer
• Michael Smolinski,
  Chief Scientific Officer